Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 7/20 | 0.46 |
| ▸ | PGR | P06401 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530948 | 0.91 | NR3C1 (0.47) | NR3C1PGRARTRPV1PDK2 | |
| SCHEMBL3532056 | 0.84 | NR3C1 (0.44) | NR3C1PGRARTRPV1LMNA | |
| SCHEMBL3535385 | 0.84 | NR3C1 (0.53) | NR3C1PGRARTRPV1 | |
| SCHEMBL3529867 | 0.83 | NR3C1 (0.50) | NR3C1PGRARTRPV1 | |
| SCHEMBL3535768 | 0.83 | NR3C1 (0.33) | NR3C1PGRARBRD4BRD9 | |
| SCHEMBL3533231 | 0.82 | NR3C1 (0.67) | NR3C1PGRARKAT2BTRPV1 | |
| SCHEMBL3538995 | 0.82 | NR3C1 (0.47) | NR3C1PGRAR | |
| SCHEMBL3534714 | 0.82 | NR3C1 (0.47) | NR3C1PGRARTRPV1 | |
| SCHEMBL3533194 | 0.82 | NR3C1 (0.49) | NR3C1PGRARTRPV1KDM4E | |
| SCHEMBL332023 | 0.81 | NR3C1 (0.45) | NR3C1PGRARTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638515-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-29 | — | — | US | disclosed |
| US-20050209324-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209324-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | TNF, DHPS, PTGES | NR3C1 1387/4885PGR 3963/4885AR 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.